News from janssen emea A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

Nov 07, 2017, 13:05 ETSTELARA® (ustekinumab) Shows Positive Results in Treatment of Systemic Lupus Erythematosus in Phase 2 Trial

FOR MEDICAL AND TRADE MEDIA ONLY 60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients...


Nov 07, 2017, 13:04 ETNew Phase 2 Data Show Treatment With TREMFYA® (guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year

FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in...


Nov 07, 2017, 07:05 ETNew Phase 2 Data Show Treatment With TREMFYA® (guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year

FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in...


Nov 07, 2017, 04:09 ETSTELARA® (ustekinumab) Shows Positive Results in Treatment of Systemic Lupus Erythematosus in Phase 2 Trial

FOR MEDICAL AND TRADE MEDIA ONLY 60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients...


Jun 14, 2017, 11:25 ETJanssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs

Sirukumab Phase 3 Data Presented at the Annual European Congress of Rheumatology (EULAR) 2017 also Show Significant Improvement in Quality of Life...


Oct 29, 2012, 02:00 ETSe publican los resultados de un Mandato de Soriasis para conmemorar el Día Mundial de la Soriasis

Muestre hoy su apoyo para ayudar a impulsar el cambio necesario que necesitan las personas con soriasis Hoy se han publicado los prometedores...


Oct 29, 2012, 02:00 ETLes résultats du Mandat du psoriasis paraissent à l'occasion de la Journée mondiale pour le psoriasis

Apportez votre soutien dès aujourd'hui pour participer au changement tant attendu par les personnes atteintes de psoriasis Les résultats provisoires...


Oct 29, 2012, 02:00 ETPubblicati i risultati del Mandato per la Psoriasi per sottolineare la Giornata Mondiale della Psoriasi

Date immediatamente il vostro sostegno per promuovere un cambiamento importantissimo a favore delle persone colpite dalla psoriasi I promettenti...


Oct 29, 2012, 02:00 ETErgebnisse des Psoriasis-Mandats veröffentlicht, um den Welt-Psoriasis-Tag einzuläuten

Gehen Sie heute die Verpflichtung ein, den Kampf um die Durchsetzung notwendiger Änderungen für Menschen mit Psoriasis zu unterstützen Heute wurden...


Oct 29, 2012, 02:00 ETPsoriasis Mandate Results Released to Mark World Psoriasis Day

Pledge Your Support Today to Help Drive Much-needed Change for People With Psoriasis Promising interim results from the Psoriasis Mandate have been...


Mar 25, 2011, 08:44 ETAssociation de Risperdal(R) Consta(R) à un risque d'hospitalisation plus faible chez les patients atteints de schizophrénie, en comparaison avec les traitements utilisant d'autres antipsychotiques

- Pour la presse médicale uniquement Les nouveaux résultats d'une étude prospective indépendante, présentés la semaine dernière lors du 19ème Congrès ...


Mar 25, 2011, 06:59 ETIl Risperdal(R) Consta(R) è associato a un minor rischio di ricovero ospedaliero rispetto alle terapie con altri antipsicotici nei pazienti schizofrenici

- Solo per i media del settore medico Nuovi dati emersi da uno studio indipendente presentato la scorsa settimana durante il diciannovesimo Congresso ...


Mar 25, 2011, 06:59 ETRisperdal(R) Consta(R) im Vergleich zur Behandlung mit anderen Antipsychotika bei Schizophreniepatienten mit geringerem Risiko einer Hospitalisierung assoziiert

- Nur für medizinische Medien Neue Ergebnisse aus einer letzte Woche beim 19. Europäischen Kongress der Psychiatrie(EPA 2011) vorgestellten...


Mar 25, 2011, 06:47 ETRisperdal(R) Consta(R) se asocia a un menor riesgo de hospitalización en pacientes esquizofrénicos

- Risperdal(R) Consta(R) se asocia a un menor riesgo de hospitalización en comparación con los tratamientos basados en otros antipsicóticos en...